Previous study has pointed out that CRC patients with POLE mutations are often accompanied with high levels of TILs, upregulated PD-L1 expression, and increased expression of cytotoxic T cell markers and effector cytokines, suggesting enhanced tumor immunogenicity [158]. The gene discussed is CD274; the disease is colorectal carcinoma.